Clinical Trial Update: Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study of the JAK inhibitor CP-690,550 (tofacitinib) in pediatric patients with Juvenile Idiopathic Arthritis; the trial is completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Juvenile Idiopathic Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2016-07-04